The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:90-93 July 3, 2003 Number 1
NextNext

Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Frohlich, E. D.
-Related Article
by Wing, L. M.H.
-PubMed Citation
To the Editor: The conflicting recommendations of the Second Australian National Blood Pressure Study (ANBP2) reported by Wing et al. (Feb. 13 issue)1 and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)2 concerning the superiority of diuretics or angiotensin-converting–enzyme (ACE) inhibitors can be reconciled. In ALLHAT, the rates of the cardiovascular disease–related end points were higher in the ACE-inhibitor group than in the diuretic group because there were more hospitalizations for heart failure and more strokes. In ANBP2, there were no significant differences in either of these end points. The higher rate of stroke in the ACE-inhibitor . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.